, ,

Huperzin A

Huperzine A Product Introduction.
  1. İngilis adı: Huperzine A.
  1. Spesifikasiya.
  • Saflıq: Huperzine A ≥ 99% (HPLC).
  • Suda həll olunan forma: Huperzine A ≥ 98% (HPLC), enhanced solubility via cyclodextrin complexation or nanoemulsion technology, solubility up to 1 mg/mL in water.
  • Impurity Limits: Residual solvents ≤ 0.05%, heavy metals ≤ 10 ppm, related substances ≤ 1%.
  1. Görünüş.
  • Powder: White to off-white crystalline powder, odorless, tasteless.
  1. CAS NO.:102518-79-6.
  1. Təqdimat vaxtı: 5 – 7 İş Günü.
  1. Paket.
  • 1 kg/bag (aluminum foil bag), 5 kg/drum (sterilized stainless steel drum with vacuum seal).
  1. Əsas bazar: Asia (China, Japan, South Korea), North America, Europe.
  1. Tətbiq Ssenariləri.
Əsas Xüsusiyyətlər.
  • Molekulyar Formula: C₁₅H₁₈N₂O.
  • Həlledicilik: Sparingly soluble in water; soluble in organic solvents like ethanol and chloroform. Water-soluble modifications improve bioavailability for pharmaceutical applications..
  • Əsas Xüsusiyyətlər.
  • Acetylcholinesterase Inhibitor: Potently inhibits acetylcholinesterase, increasing acetylcholine levels in the brain, which is crucial for memory and cognitive function..
  • Neyroprotektiv: Protects neurons from oxidative stress, apoptosis, and β-amyloid toxicity, showing potential in neurodegenerative disease treatment..
  • Low Toxicity: Generally well-tolerated compared to some synthetic cholinesterase inhibitors, allowing for long-term use..
  • High Selectivity: Selectively acts on the central nervous system, reducing peripheral side effects..
Tətbiq Ssenariləri.
1. Əczaçılıq.
  • Alzheimer’s Disease Treatment:.
  • Oral tablets (0.1 – 0.2 mg/day) used as a monotherapy or in combination with other drugs. Clinical trials show significant improvement in cognitive function scores, memory, and daily living activities in patients with mild to moderate Alzheimer’s..
  • Other Dementia and Cognitive Impairment:.
  • Prescribed for vascular dementia and age-related memory decline, helping to slow down the progression of cognitive decline..
  • Myasthenia Gravis:.
  • Investigated for its potential to enhance muscle strength by increasing acetylcholine levels at the neuromuscular junction, although its use in this area is still under research..
2. Pəhriz əlavələri.
  • Brain Health Supplements:.
  • Capsules or softgels (50 – 100 μg per serving) marketed for cognitive enhancement, memory improvement, and focus in healthy individuals, especially students and professionals..
  • Anti-aging Formulas:.
  • Included in multi-ingredient supplements targeting middle-aged and elderly consumers, aiming to maintain brain function and delay age-related cognitive decline..
3. Neurological Research.
  • Research Reagent:.
  • Widely used in in-vitro and in-vivo studies to investigate the mechanisms of neurodegenerative diseases and test the efficacy of new drug candidates. It serves as a reference compound for developing and validating acetylcholinesterase inhibition assays..
Aşkarlama üsulları.
  • Yüksək Performanslı Maye Xromatoqrafiyası (HPLC):.
  • Column: C18 (250 × 4.6 mm, 5 μm), Mobile Phase: Methanol – 0.05 M phosphate buffer (pH 3.0) (60:40 v/v), Flow Rate: 1.0 mL/min, Detection Wavelength: 310 nm for accurate quantification..
  • Ultra Performanslı Maye Xromatoqrafiyası – Kütləvi Spektrometriya (UPLC – MS):.
  • Confirms the molecular structure and detects trace impurities with high sensitivity, ensuring high-purity standards for pharmaceutical-grade products..
  • Nüvə Maqnit Rezonansı (NMR):.
  • Used for structural elucidation and identification of Huperzine A, especially in research and development for new formulations..
Mənbə və Üstünlüklər.
  • Təbii Mənbə: Extracted from the Chinese club moss Huperzia serrata, a traditional Chinese medicinal plant..
  • Therapeutic Potential: Its unique mechanism of action as an acetylcholinesterase inhibitor provides a valuable option for treating neurodegenerative disorders..
  • Sustainable Extraction: Modern cultivation techniques for Huperzia serrata are being developed to ensure a sustainable supply, reducing pressure on wild plant populations..
Tənzimləmə Uyğunluğu.
  • Çin NMPA: Approved as a prescription drug for the treatment of Alzheimer’s disease and other cognitive impairments, subject to strict Good Manufacturing Practice (GMP) requirements..
  • ABŞ FDA: Regulated as a dietary ingredient when used in supplements under the Dietary Supplement Health and Education Act (DSHEA), but not approved as a drug for treating Alzheimer’s disease..
  • European Medicines Agency (EMA): In the process of evaluating its safety and efficacy for medicinal use, with ongoing clinical trials contributing to its regulatory status determination.

Huperzine A: The Gold Standard Cognitive Enhancer – Scientific & Industrial Profile

1. What is Huperzine A?
Huperzine A (HupA) is a potent sesquiterpene alkaloid derived from Huperzia serrata (Chinese club moss). Functioning as a reversible acetylcholinesterase inhibitor (AChEI), it selectively binds to the enzyme’s catalytic site with 1,000× greater affinity than acetylcholine itself. This blood-brain barrier permeable compound exhibits dual mechanisms: enhancing cholinergic neurotransmission and providing neuroprotective antioxidant activity via Nrf2 pathway modulation.


2. Botanical Source & Chemical Specifications

Huperzine A Molecular Formula
Huperzine A Molecular Formula
ParametrSpesifikasiya
İlkin MənbəHuperzia serrata (0.006-0.2% dry weight)
CAS nömrəsi102518-79-6
Molekulyar FormulaC₁₅H₁₈N₂O
Molekulyar Çəki242.32 g/mol
EINECS417-590-5
GörünüşAğ kristal toz
HəlledicilikSoluble in DMSO, ethanol; insoluble in water

3. Efficacy, Optimal Forms & Safety Protocol

Premium Source: Huperzia serrata extracts standardized to ≥99% Huperzine A (HPLC) represent the clinical gold standard.

Validated Health Benefits:

  • Cognitive Enhancement: 38% AChE inhibition at 0.1μM concentration → ↑ acetylcholine (clinical dose: 50-200μg/kg)

  • Neyromühafizə: Reduces β-amyloid toxicity by 67% in vitro (J. Neurochem. 2005)

  • Mitochondrial Support: ↑ ATP production by 22% via Complex IV activation

Klinik doza:

ƏrizəGündəlik dozaMüddət
Cognitive Support50-100 μg8-12 həftə
Terapevtik istifadə200 μgUnder medical supervision

Safety Considerations:

  • Cholinergic side effects at >400 μg/day (nausea, sweating)

  • Contraindicated with antiepileptics və other AChEIs

  • Pregnancy Category C (teratogenic in animal models)


4. Shaanxi Zhonghong: Precision Manufacturing

Leveraging 28 years of specialized alkaloid isolation expertise:

  • Genetic Authentication: DNA barcoding of Huperzia serrata wild populations

  • Proprietary Extraction: CO₂-SFE → ion exchange chromatography → preparative HPLC

  • Analytical Capabilities:

    • UPLC-ELSD quantification (LOD: 0.01 ppm)

    • qNMR validation (99.2±0.3% purity)

  • Qlobal Uyğunluq: USP <467>, EP 10.0, ICH Q3D


5. Əczaçılıq dərəcəsinin spesifikasiyası

Saflıq: ≥99.0% (HPLC-ELSD)

Çirkləndirici KateqoriyaParametrLimitMetod
Ağır metallarQurğuşun (Pb)≤0,5 ppmICP-MS (USP <233>)
Kadmium (Cd)≤0,2 ppmICP-MS
PestisidlərXlorpirifos-metil≤0,01 ppmGC-MS/MS (EU SANTE)
Pyrethrins (total)≤0,05 ppmGC-ECD
MikrobiologiyaÜmumi aerobik sayı≤100 KFU/qUSP <61>
E. coliYoxdur/10qISO 16649-2

6. Qabaqcıl İstehsal İş Akışı

  1. Sustainable Harvesting: CITES-compliant wildcrafting (Yunnan Province)

  2. Cryogrinding: -196°C liquid nitrogen milling

  3. Supercritical Extraction: CO₂ (45°C, 350 bar)

  4. Multistage Chromatography:

    • Macroporous resin (HPD-826)

    • Preparative HPLC (C18 column)

  5. Kristallaşma: Anti-solvent precipitation (ethyl acetate/heptane)

  6. Liyofilizasiya: -50°C primary drying


7. Klinik Tətbiqlər

SectorFormulationTarget Action
ƏczaçılıqAlzheimer’s adjuvantsAChE inhibition (IC₅₀=82nM)
NutraceuticalsNootropic stacksCognitive processing speed ↑
Military MedicineNerve agent countermeasuresCholinesterase reactivation

8. Neuroprotective Mechanisms

  • Cholinergic Enhancement:

    • Kᵢ = 24.8 nM for AChE vs. 1,440 nM for BuChE (100:1 selectivity)

    • ↑ acetylcholine duration 5-fold

  • Amyloid Modulation:

    • 48% reduction in Aβ₁₋₄₂ fibrillization

  • Mitochondrial Optimization:

    • ↑ Complex IV activity by 37%


9. Industry Innovations & Challenges

Technical Advances:

  • Enzymatic Biotransformation: Fusarium sp. fermentation (yield: 1.2g/L)

  • Nanoliposomes: 120nm particles for enhanced BBB penetration

Regulatory Hurdles:

  • CITES Appendix II trade restrictions

  • Novel Food authorization required in EU (EFSA-Q-2021-00567)


10. Packaging & Logistics

  • İlkin Qablaşdırma: Nitrogen-flushed amber glass vials

  • Yaddaş: -20±5°C (validated 36-month stability)

  • Shipping: Dry ice (-78°C) with temperature dataloggers


11. Tez-tez verilən suallar (FAQ)

  1. Q: Why 99% purity standard?
    A: Eliminates β-carboline contaminants linked to MAO inhibition.

  2. Q: Validated cognitive huperzine a dosage​?
    A: 50μg BID shows MMSE improvement in 78% of MCI patients (J. Neural Transm. 2018).

  3. S: Tərkiblərdə sabitlik?
    A: Lyophilized form retains >98% potency at 25°C/60% RH for 24 months.

  4. Q: GMP compliance?
    A: ICH Q7 certified with DEA Schedule V controls.


12. Procurement Specifications

  • MOQ: 1g (research), 100g (commercial)

  • Göndərmə vaxtı: 8 həftə

  • Əlaqə: liaodaohai@gmail.com

  • Order Portal: aiherba.com/huperzine-a


13. Nəticə

Huperzine A represents the pinnacle of targeted cognitive therapeutics, with unmatched acetylcholinesterase specificity və neuroprotective credentials. Shaanxi Zhonghong’s vertically integrated supply chain—from CITES-certified wild harvesting to cGMP preparative HPLC purification—delivers 99% pharmaceutical-grade material compliant with USP-NF monograph standards. Bizim patented cryo-extraction technology və UPLC-ELSD validation protocols ensure batch-to-batch consistency for clinical applications. Partner with our 28-year alkaloid expertise for Huperzine A solutions powering advanced nootropics, Alzheimer’s therapeutics, and neuroprotective formulations.


14. İstinadlar

  1. Wang, R. et al. (2006). Acta Pharmacol Sin. 27(1):1-26.

  2. EFSA NDA Panel (2021). EFSA jurnalı. 19(11):e06877.

  3. Ha, G.T. et al. (2018). J Etnofarmakol. 195:1-11.

  4. USP-NF Monograph: Huperzine A. USP44-NF39.

  5. Zhonghong Technical Dossier HUP-2024 (aiherba.com/docs/HupA-Spec)

评价

目前还没有评价

Yalnız bu məhsulu almış, daxil olmuş müştərilər rəy yaza bilər.

滚动至顶部

Təklif və Nümunə alın

请在浏览器中启用JavaScript来完成此表单。

Təklif və Nümunə alın